SCHEMBL15618198

SCHEMBL15618198

O=C(O)c1c[nH]c2ncnc(Nc3ccc4[nH]c(=O)sc4c3)c12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 9/20 0.53
▸ EGFR P00533 2/20 0.41
▸ CDC7 O00311 2/20 0.41
▸ ROCK2 O75116 1/20 0.41
▸ MAP4K4 O95819 1/20 0.41
▸ PIM1 P11309 1/20 0.41
▸ PRKACA P17612 1/20 0.41
▸ CDK2 P24941 1/20 0.41
▸ GSK3B P49841 1/20 0.41
▸ HIPK2 Q9H2X6 1/20 0.41
▸ CLK4 Q9HAZ1 1/20 0.41
▸ IRAK4 Q9NWZ3 1/20 0.41
▸ KIF11 P52732 1/20 0.40
▸ SYK P43405 1/20 0.40
▸ CSNK2A2 P19784 1/20 0.39
▸ CSNK2B P67870 1/20 0.39
▸ CSNK2A1 P68400 1/20 0.39
▸ BRAF P15056 1/20 0.38
▸ TNNI3K Q59H18 1/20 0.38
▸ MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15618313 0.88 MKNK1 (0.62) MKNK1CDC7ROCK2MAP4K4PIM1
SCHEMBL15618243 0.86 MKNK1 (0.49) MKNK1ROCK2IRAK4MAPTSMN1; SMN2
SCHEMBL18167320 0.85 MKNK1 (0.51) MKNK1EGFRCDC7ROCK2MAP4K4
SCHEMBL17026139 0.84 MKNK1 (0.66) MKNK1EGFRCDC7ROCK2MAP4K4
SCHEMBL17026036 0.84 MKNK1 (0.57) MKNK1EGFRKIF11SYKBRAF
SCHEMBL15618235 0.84 MKNK1 (0.56) MKNK1EGFRKIF11SYKBRAF
SCHEMBL15618350 0.83 MKNK1 (0.53) MKNK1EGFR
SCHEMBL15618203 0.81 MKNK1 (0.53) MKNK1EGFRIRAK4KIF11SYK
SCHEMBL15618290 0.78 MKNK1 (0.55) MKNK1EGFRKIF11SYKCSNK2A2
SCHEMBL15618645 0.75 MKNK1 (0.66) MKNK1EGFRKIF11SYKMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2897957-B1 SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS Bayer Pharma AG (DE) 2016-10-26 — — EP claimed
CN-104797582-B Substituted pyrrolo-pyrimidine radicals amino-benzothiazole ketone as MKNK inhibitors of kinases 拜耳药业股份公司 2016-10-12 — — CN claimed
US-9382255-B2 Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-07-05 — — US claimed
US-20150239891-A1 SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-08-27 — — US claimed
EP-2897957-A1 SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2015-07-29 — — EP claimed
WO-2014044691-A1 SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-03-27 — — WO claimed
EP-2897957-B1 SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS Bayer Pharma AG (DE) 2016-10-26 — — EP disclosed
EP-2897957-B1 SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS Bayer Pharma AG (DE) 2016-10-26 — — EP disclosed
CN-104797582-B Substituted pyrrolo-pyrimidine radicals amino-benzothiazole ketone as MKNK inhibitors of kinases 拜耳药业股份公司 2016-10-12 — — CN disclosed
US-9382255-B2 Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-07-05 — — US disclosed
US-9382255-B2 Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-07-05 — — US disclosed
US-20150239891-A1 SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-08-27 — — US disclosed
US-20150239891-A1 SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-08-27 — — US disclosed
EP-2897957-A1 SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2015-07-29 — — EP disclosed
CN-104797582-A Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase inhibitors Bayer Pharma AG 2015-07-22 — — CN disclosed
WO-2014044691-A1 SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-03-27 — — WO disclosed
WO-2014044691-A1 SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-03-27 — — WO disclosed
US-20100113606-A1 AMINOPROPANOL MODULATORS OF BETA-1 ADRENERGIC RECEPTOR AUSPEX PHARMACEUTICALS, INC. (US) 2010-05-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113606-A1 AMINOPROPANOL MODULATORS OF BETA-1 ADRENERGIC RECEPTOR ADRB1, ADRB2, ADRB3 MKNK1 3686/4885EGFR 3969/4885CDC7 3837/4885
US-20150239891-A1 SUBSTITUTED PYRROLOPYRIMIDINYLAMINO-BENZOTHIAZOLONES AS MKNK KINASE INHIBITORS MKNK1, MKNK2, MAP3K20 MKNK1 1/4885EGFR 828/4885CDC7 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback